Company news

Pyxis Oncology, Inc. news in 2026

Pyxis Oncology, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)

November 5, 2026

Pyxis Oncology to Participate in Upcoming Investor Conferences

October 28, 2026

Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 27, 2026

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

October 2, 2026

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

September 30, 2026

Pyxis Oncology Announces Proposed Public Offering

September 29, 2026

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

September 9, 2026

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

September 8, 2026

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

September 8, 2026

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

August 13, 2026

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

June 30, 2026

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

May 13, 2026

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

May 7, 2026

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

April 17, 2026

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

March 22, 2026

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

February 3, 2026

Decks in 2026